Precipio AI Stock Analysis
Want to see PRPO full AI Analyst Report?
Precipio (PRPO) AI Stock Analysis
Precipio
(NASDAQ:PRPO)
The score is driven primarily by improving fundamentals—strong revenue expansion and a meaningful turn to positive operating/free cash flow supported by modest leverage—tempered by continued net losses and negative returns. Technical signals are notably weak (negative MACD, low RSI, and trading below longer-term moving averages), and valuation is constrained by a negative P/E with no dividend support. The latest earnings call adds some upside from positive sentiment and clear growth targets, but execution risks remain due to slower pathology growth and long sales/onboarding cycles.
Precipio (PRPO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $39.68M
- Dividend Yield
- ―
- Average Volume (3M)
- 91.01K
- Price to Earnings (P/E)
- -36.6
- Beta (1Y)
- 0.69
- Revenue Growth
- 21.76%
- EPS Growth
- 22.97%
- Country
- US
- Employees
- 61
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Precipio Business Overview & Revenue Model
Company Description
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood ca...
Precipio Earnings Call Summary
The call was predominantly positive. Management highlighted cash-flow positivity, a cash balance above $3.5 million, the first quarter with product revenue above $1 million, established distribution and commercial infrastructure, and ambitious 2027 revenue targets. The main challenges were that product growth remains below management's expectations, pathology growth has slowed, and customer onboarding and sales-representative ramp times are long. Management nevertheless expressed confidence in its pipeline and its ability to accelerate growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2027, Precipio is targeting product-division annual revenue run rate exceeding $10 million by the end of 2027, compared with approximately $4 million annualized based on Q3 2026 results; pathology annualized revenue run rate of approximately $30 million by the end of 2027; and combined annualized revenue run rate exceeding $40 million by the end of 2027, with these targets representing the annualized revenue run rate they aim to achieve as they exit 2027 rather than a forecast of total revenue recognized during the year. The current sales force is 4, with plans for doubling that next year and to hire probably 2 more folks at least by the beginning of the year; pathology may add 1 or 2 more reps. Customer onboarding is probably somewhere between 3 months and 18 months, averaging between 9 and 12 months from initial conversation to go live. Product gross margin is currently around the kind of high 40s, 50% gross margin, expected to reach probably the mid-60s when revenue doubles and, at a higher scale, a good 70%, 75% gross margin; product revenue growth goals include $0.25 million and $0.5 million of new revenue coming in each quarter.
Precipio Financial Statement Overview
Summary
Revenue has improved materially (to $28.6M TTM) with steady mid-40% gross margins and a conservative balance sheet (debt-to-equity ~0.23). Cash flow has turned positive (TTM operating cash flow $1.7M; free cash flow $1.39M), but net income remains negative in TTM (-$1.1M) and ROE is still negative, indicating the business has not yet converted progress into consistent profitability.
Income Statement
52NeutralBalance Sheet
71PositiveCash Flow
64Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.63M | 24.05M | 15.96M | 15.20M | 9.41M | 8.85M |
| Gross Profit | 12.37M | 10.71M | 7.56M | 6.02M | 2.51M | 2.39M |
| EBITDA | 235.00K | 1.46M | -2.70M | -4.32M | -10.65M | -7.05M |
| Net Income | -1.14M | -363.00K | -4.29M | -5.85M | -12.20M | -8.55M |
Balance Sheet | ||||||
| Total Assets | 21.71M | 21.32M | 17.00M | 18.10M | 21.50M | 30.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.58M | 6.04M | 1.39M | 1.50M | 3.44M | 11.67M |
| Total Debt | 3.69M | 3.65M | 1.25M | 1.12M | 1.39M | 1.43M |
| Total Liabilities | 6.85M | 6.76M | 4.90M | 3.67M | 5.14M | 5.83M |
| Stockholders Equity | 14.87M | 14.56M | 12.09M | 14.43M | 16.30M | 24.56M |
Cash Flow | ||||||
| Free Cash Flow | 1.39M | 359.00K | 216.00K | -3.69M | -8.00M | -7.26M |
| Operating Cash Flow | 1.70M | 685.00K | 439.00K | -3.56M | -7.72M | -6.58M |
| Investing Cash Flow | -313.00K | -326.00K | -223.00K | -126.00K | -277.00K | -682.00K |
| Financing Cash Flow | -116.00K | 903.00K | -329.00K | 1.74M | -225.00K | 16.27M |
Precipio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPO, the sentiment is Neutral. The current price of 22.13 is above the 20-day moving average (MA) of 20.45, below the 50-day MA of 22.97, and below the 200-day MA of 24.82, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.48 is Neutral, neither overbought nor oversold. The STOCH value of 73.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRPO.
Precipio Risk Analysis
Precipio disclosed 62 risk factors in its most recent earnings report. Precipio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPrecipio Peers Comparison
Overall Rating
NTRA63Neutral- PRPO56Neutral
NEO54Neutral
MYGN47Neutral
BDSX45Neutral
GH44.3Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NTRA | 63Neutral | $46.27B | -279.90 | -9.18% | ― | 37.43% | 49.82% |
| PRPO | 56Neutral | $39.68M | -36.61 | -7.84% | ― | 21.76% | 22.97% |
| NEO | 54Neutral | $2.07B | -64.91 | -3.97% | ― | 11.08% | 71.76% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MYGN | 47Neutral | $542.92M | -4.15 | -40.40% | ― | -2.63% | 68.56% |
| BDSX | 45Neutral | $109.55M | -3.58 | -442.34% | ― | 31.23% | 48.56% |
| GH | 44Neutral | $20.52B | -41.22 | 249.03% | ― | 41.69% | -14.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRPO | Precipio | 22.13 | 1.10 | 5.23% | |
| MYGN | Myriad Genetics | 5.66 | -1.00 | -15.02% | |
| NEO | NeoGenomics Inc. | 16.02 | 5.80 | 56.75% | |
| NTRA | Natera Inc. | 319.09 | 113.05 | 54.87% | |
| GH | Guardant Health | 151.70 | 55.22 | 57.23% | |
| BDSX | Biodesix, Inc. | 9.88 | 1.96 | 24.75% |
Precipio Corporate Events
Precipio Announces Q3 2026 Shareholder Update Call
PositiveSpecialty cancer diagnostics company Precipio, Inc. said on October 28, 2026, that it will host its Q3 2026 shareholder update call on November 10, 2026, at 5:00 p.m. ET, covering performance across its core businesses and featuring a moderated live...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026